Table 3.
Follow-up and ablation outcomes by DM status
| Outcomes | DM (N = 65) | No DM (N = 286) | Total (N = 351) | P value |
|---|---|---|---|---|
| Periprocedural complications | .868‡ | |||
| Access site bleeding | 1 (1.5) | 4 (1.4) | 5 (1.4) | |
| Stroke/TIA | 0 (0.0) | 3 (1.0) | 3 (0.9) | |
| Acute heart failure | 1 (1.5) | 3 (1.0) | 4 (1.1) | |
| Proarrhythmia (AT/AFL) | 1 (1.5) | 4 (1.4) | 5 (1.4) | |
| Phrenic nerve paralysis | 1 (1.5) | 1 (0.3) | 2 (0.6) | |
| Urinary tract infection | 1 (1.5) | 7 (2.4) | 8 (2.3) | |
| Pericardial effusion/tamponade | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Any monitoring∗ | 39 (60.0) | 178 (62.2) | 217 (61.8) | .738§ |
| Ambulatory monitoring (mo)† | 35 (53.8) | 157 (54.9) | 192 (54.7) | .878§ |
| 3 | 6 (17.1) | 58 (36.9) | 64 (33.3) | .029‡ |
| 6 | 10 (28.6) | 58 (36.9) | 68 (35.4) | .349§ |
| 9 | 9 (25.7) | 24 (15.3) | 33 (17.2) | .144‡ |
| 12 | 4 (11.4) | 20 (12.7) | 24 (12.5) | 1‡ |
| 18 | 10 (28.6) | 26 (16.6) | 36 (18.8) | .010§ |
| ≥24 | 23 (65.7) | 63 (40.1) | 86 (44.8) | .006§ |
| Ablation outcome | ||||
| AF recurrence | 37 (56.9) | 97 (33.9) | 134 (38.2) | .001§ |
| AF symptoms | 21 (32.3) | 83 (29.0) | 104 (29.6) | .600§ |
| AAD use | .001‡ | |||
| Amiodarone | 15 (23.1) | 19 (6.6) | 34 (9.7) | |
| Class IC | 3 (4.6) | 14 (4.9) | 17 (4.8) | |
| Class III | 11 (16.9) | 41 (14.3) | 52 (14.8) | |
| None | 36 (55.4) | 212 (74.1) | 248 (70.7) | |
| Repeat ablations | 16 (24.6) | 57 (19.9) | 73 (20.8) | .401§ |
| All-cause hospitalization | 19 (29.2) | 62 (21.7) | 81 (23.1) | .192§ |
| Cardiovascular hospitalization | 10 (15.4) | 43 (15.0) | 53 (15.1) | .065‡ |
| Arrhythmia | 8 (80.0) | 24 (55.8) | 32 (60.4) | |
| Heart failure | 0 (0.0) | 11 (25.6) | 11 (20.8) | |
| Myocardial infarction | 0 (0.0) | 3 (7.0) | 3 (5.7) | |
| Significant bleeding | 0 (0.0) | 4 (9.3) | 4 (7.5) | |
| Stroke/TIA | 2 (20.0) | 1 (2.3) | 3 (5.7) |
Values are given as n (%) unless otherwise indicated.
AFL = atrial flutter; AT = atrial tachycardia; other abbreviations as in Table 1.
∗
Any monitoring includes monitoring by device interrogation or ambulatory monitoring beyond routine electrocardiographic monitoring.
†
Ambulatory monitoring includes Holter monitor, event monitor, and implantable loop recorder.
‡
Fisher exact test.
§
χ2 test.